Supplementary Table 7 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis

Chun-Miao Deng,Guo-Geng Zhang,Qin-Wen Liu,Jiao-Jiao Xu,Zhi-Chao Liu,Jing Yang,Tao-Yang Xu,Zhi-Gang Li,Fan Zhang,Bin Li

DOI: https://doi.org/10.1158/0008-5472.22929959

2023-01-01

Abstract:Supplementary Table 7 shows Human transcription factor in ANO1 interacting proteins detected by IP-MS

What problem does this paper attempt to address?

Supplementary Table 6 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis

Chun-Miao Deng,Guo-Geng Zhang,Qin-Wen Liu,Jiao-Jiao Xu,Zhi-Chao Liu,Jing Yang,Tao-Yang Xu,Zhi-Gang Li,Fan Zhang,Bin Li

DOI: https://doi.org/10.1158/0008-5472.22929962.v1

2023-01-01

Abstract:Supplementary Table 6 shows DEGs of EC9706 overexpressing ANO1 and control cells
Supplementary Table 5 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis

Chun-Miao Deng,Guo-Geng Zhang,Qin-Wen Liu,Jiao-Jiao Xu,Zhi-Chao Liu,Jing Yang,Tao-Yang Xu,Zhi-Gang Li,Fan Zhang,Bin Li

DOI: https://doi.org/10.1158/0008-5472.23283285.v1

2023-01-01

Abstract:Supplementary Table 5 shows Correlation between ANO1 expression levels and clinicopathological parameters in 100 cases of esophageal cancer
Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528410.v1

2023-01-01

Abstract:PDF file, 95K, Antibodies used in reverse-phase protein microarrays
Supplementary Figure from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis

Chun-Miao Deng,Guo-Geng Zhang,Qin-Wen Liu,Jiao-Jiao Xu,Zhi-Chao Liu,Jing Yang,Tao-Yang Xu,Zhi-Gang Li,Fan Zhang,Bin Li

DOI: https://doi.org/10.1158/0008-5472.23283270

2023-01-01

Abstract:Supplementary figures shows Supplementary figures and figure legends
ANO1 reprograms cholesterol metabolism and the tumor microenvironment to promote cancer metastasis

Chun-Miao Deng,Guo-Geng Zhang,Qin-Wen Liu,Jiao-Jiao Xu,Zhi-Chao Liu,Jing Yang,Tao-Yang Xu,Zhi-Gang Li,Fan Zhang,Bin Li

DOI: https://doi.org/10.1158/0008-5472.can-22-3490

IF: 11.2

2023-03-15

Cancer Research

Abstract:Tumor metastasis is a complex process. A better understanding of the mechanistic underpinnings of the metastatic cascade could uncover approaches to better prevent and target metastases. Here, we integrated transcriptomic profiling in primary esophageal squamous cell carcinoma (ESCC) and matched lymph node metastatic tissues and genome-wide CRISPR/Cas9 functional screening to identify the key drivers of cancer metastasis. Anoctamin 1 (ANO1) expression was found to be elevated in primary tumors and further increased in metastatic tissues. High expression of ANO1 was associated with poor patient survival, and ANO1 overexpression promoted cancer invasion and metastasis. Mechanistically, ANO1 inactivated the LXR pathway and increased intracellular cholesterol accumulation by interacting with JUN to repress the transcription of cholesterol hydroxylase, CYP27A1. In a paracrine manner, interleukin 1β (IL-1β) secreted from ANO1-expressing ESCC cancer cells activated NFκB signaling in fibroblasts to stimulate production of the chemokine CCL1, which in turn enhanced invasion of ESCC cancer cells. Furthermore, molecular docking and in silico screening of 1,500,000 small molecules identified K786-4469 as a lead compound that targeted ANO1 and suppressed cancer metastasis in vitro and in vivo. Overall, these findings uncover a non-canonical function of ANO1 in regulating cholesterol metabolism and fibroblast function, revealing ANO1 as a potential prognostic biomarker and therapeutic target for metastatic ESCC.

oncology
High ANO1 expression is a prognostic factor and correlated with an immunosuppressive tumor microenvironment in pancreatic cancer

Guangnian Zhang,Zhihui Shu,Jun Yu,Jianshui Li,Pengsheng Yi,Bin Wu,Dawei Deng,Shu Yan,Yong Li,Dongmei Ren,Yifu Hou,Chuan Lan

DOI: https://doi.org/10.3389/fimmu.2024.1341209

IF: 7.3

2024-01-31

Frontiers in Immunology

Abstract:Background: Aminooctylamine (ANO1) plays an oncogenic role in various cancers. However. its role in pancreatic cancer (PC) has rarely been studied. This study investigated the prognostic value of ANO1 and its correlation with the tumor microenvironment (TME) in PC. Methods: Consecutive patients with PC (n = 119) were enrolled. The expression of ANO1 in cancer cells, the expression of fibroblast activation protein (FAP) and alpha smooth muscle actin in cancer-associated fibroblasts (CAFs), and the numbers of CD8- and FOXP3-positive tumor-infiltrating lymphocytes (TILs) were evaluated using immunohistochemistry. The prognostic value of ANO1 and its correlation with CAF subgroups and TILs were analyzed. The possible mechanism of ANO1 in the TME of PC was predicted using the the Cancer Genome Atlas (TCGA) dataset. Results: The expression of AN01 was correlated with overall survival (OS) and disease-free survival. Multi-factor analysis showed that high ANO1 expression was an independent adverse prognostic factor for OS (hazard ratio, 4.137; P = 0.001). ANO1 expression was positively correlated with the expression of FAP in CAFs (P < 0.001) and negatively correlated with the number of CD8-positive TILs (P = 0.005), which was also validated by bioinformatics analysis in the TCGA dataset. Moreover, bioinformatic analysis of the TCGA dataset revealed that ANO1 may induce an immunosuppressive tumor microenvironment in pancreatic cancer in a paracrine manner. Conclusion: ANO1 is a prognostic factor in patients with PC after radical resection. ANO1 may induce an immunosuppressive tumor microenvironment in PC in a paracrine manner, suggesting that ANO1 may be a novel therapeutic target.

immunology
Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419831

2023-01-01

Abstract:Supplementary Table S1. Primers for qRT-PCR and MSP
Identification And Characterization Of Ano9 In Stage Ii And Iii Colorectal Carcinoma

Chunxiang Li,Sanjun Cai,Xishan Wang,Zheng Jiang

DOI: https://doi.org/10.18632/oncotarget.4979

2015-01-01

Oncotarget

Abstract:Background and Objectives: The precise role and potential underlying mechanisms of anoctamin 9 (ANO9) remain largely unknown. This study aims to characterize the role and oncogenic mechanisms of ANO9 in stage II and III colorectal cancer (CRC).Methods: We examined the expression of ANO9 in colorectal cancerous tissues and cells using real-time quantitative PCR and immunohistochemistry, respectively. Multiple cellular and molecular approaches such as gene transfection, CCK-8 assay, flow cytometry, and invasion assay were also performed to explore its oncogenic mechanisms. Furthermore, the clinical significance of ANO9 in clinical CRC specimens was assessed by clinical correlation and survival analyses.Results: Lower expression of ANO9 messenger RNA (mRNA) was frequently detected both in CRC tissues with recurrence and metastasis-derived cell lines. Compared with matched nontumorous tissues, lower expression of ANO9 protein was observed in tumors, which was significantly correlated with tumorigenesis (p < 0.05). In vitro functional studies showed that ANO9 contributed to tumor cell proliferation, apoptosis, and invasion. Moreover, investigation of clinical CRC specimens showed that ANO9 were markedly overexpressed in metastatic tissue compared with primary tissue. Decreased expression of ANO9 was correlated with poor prognostic outcomes.Conclusions: This study highlighted the role of ANO9 in progression and metastasis of stage II and III CRC. These findings suggested that up-regulation of ANO9, as a metastasis-related gene, could be a novel approach for inhibiting CRC progression.
Table S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419828

2023-01-01

Abstract:Supplementary Table S2. Patient characteristics
ANO1‐Mediated Inhibition of Cancer Ferroptosis Confers Immunotherapeutic Resistance through Recruiting Cancer‐Associated Fibroblasts

Fangli Jiang,Keren Jia,Yang Chen,Congcong Ji,Xiaoyi Chong,Zhongwu Li,Feilong Zhao,Yuezong Bai,Sai Ge,Jing Gao,Xiaotian Zhang,Jian Li,Lin Shen,Cheng Zhang

DOI: https://doi.org/10.1002/advs.202300881

IF: 15.1

2023-06-22

Advanced Science

Abstract:This work highlights ANO1 as a promising target for gastrointestinal (GI) cancers' precision treatment. ANO1 is highly amplified or expressed in GI cancers. Through inhibiting cancer cell ferroptosis in a PI3K‐Akt‐dependent manner, ANO1 stimulates the production and secretion of TGF‐β by cancer cells, subsequently strengthens cancer‐associated fibroblast recruitment, and cripples CD8+ T cell‐mediated anti‐tumor immune responses, generating resistance to immunotherapy. The application of immunotherapy in gastrointestinal (GI) cancers remains challenging because of the limited response rate and emerging therapeutic resistance. Combining clinical cohorts, multi‐omics study, and functional/molecular experiments, it is found that ANO1 amplification or high‐expression predicts poor outcomes and resistance to immunotherapy for GI cancer patients. Knocking‐down or inhibiting ANO1 suppresses the growth/metastasis/invasion of multiple GI cancer cell lines, cell‐derived xenograft, and patient‐derived xenograft models. ANO1 contributes to an immune‐suppressive tumor microenvironment and induces acquired resistance to anti‐PD‐1 immunotherapy, while ANO1 knockdown or inhibition enhances immunotherapeutic effectiveness and overcomes resistance to immunotherapy. Mechanistically, through inhibiting cancer ferroptosis in a PI3K‐Akt signaling‐dependent manner, ANO1 enhances tumor progression and facilitates cancer‐associated fibroblast recruitment by promoting TGF‐β release, thus crippling CD8+ T cell‐mediated anti‐tumor immunity and generating resistance to immunotherapy. This work highlights ANO1's role in mediating tumor immune microenvironment remodeling and immunotherapeutic resistance, and introduces ANO1 as a promising target for GI cancers' precision treatment.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
Role of ANO1 in Tumors and Tumor Immunity

Haini Li,Zongxue Yu,Haiyan Wang,Ning Wang,Xueguo Sun,Shengmei Yang,Xu Hua,Zongtao Liu

DOI: https://doi.org/10.1007/s00432-022-04004-2

2022-01-01

Journal of Cancer Research and Clinical Oncology

Abstract:Dysregulation of gene amplification, cell-signaling–pathway transduction, epigenetic and transcriptional regulation, and protein interactions drives tumor-cell proliferation and invasion, while ion channels also play an important role in the generation and development of tumor cells. Overexpression of Ca 2+ -activated Cl- channel anoctamin 1 (ANO1) is shown in numerous cancer types and correlates with poor prognosis. However, the mechanisms involved in ANO1-mediated malignant cellular transformation and the role of ANO1 in tumor immunity remain unknown. In this review, we discuss recent studies to determine the role of ANO1 in tumorigenesis and provide novel insights into the role of ANO1 in the context of tumor immunity. Furthermore, we analyze the roles and potential mechanisms of ANO1 in different types of cancers, and provide novel notions for the role of ANO1 in the tumor microenvironment and for potential use of ANO1 in clinical applications. Our review shows that ANO1 is involved in tumor immunity and microenvironment, and may, therefore, be an effective biomarker and therapeutic drug target.
Supplementary Table 1 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER+ Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Yan Lü,Ming You,Zara Ghazoui,Pengyuan Liu,Peter T. Vedell,Wen Wang,Ann M. Bode,Clinton J. Grubbs,Ronald A. Lubet

DOI: https://doi.org/10.1158/1940-6207.22524285

2023-01-01

Abstract:XLSX file - 87K, Gene Expression Changes Comparing Control Rat Tumors and Rat Tumors Treated with Vorozole
Figure S6 from Consistent and Differential Genetic Aberrations between Esophageal Dysplasia and Squamous Cell Carcinoma Detected By Array Comparative Genomic Hybridization

Zhi-Zhou Shi,Li Shang,Yan-Yi Jiang,Jia-Jie Hao,Yu Zhang,Tong-Tong Zhang,De-Chen Lin,Shu-Guang Liu,Bo-Shi Wang,Ting Gong,Qi-Min Zhan,Ming-Rong Wang

DOI: https://doi.org/10.1158/1078-0432.22450374

2023-01-01

Abstract:Effect of ANO1 on cell proliferation. Knock-down the expression of ANO1 inhibited the cell proliferation of KYSE30 (A) and KYSE510 cells (B). The absorbance at 450 nm was measured.
High level of ANO1 promotes pancreatic cancer growth in concert with oncogenic KRAS

Lei Zhang,Hao Wang,Jian Guo,Huijing Xu,Yihua Qian,Meiyan Sun

DOI: https://doi.org/10.1007/s11033-023-08293-9

IF: 2.7422

2023-01-31

Molecular Biology Reports

Abstract:Anoctamin-1 (ANO1) was identified as an unfavorable prognostic marker in pancreatic cancer. However, the exact implication of ANO1 in pancreatic cancer is still poorly understood. Here we investigated the effect of ANO1 in pancreatic cancer progression under the context of oncogenic KRAS , aiming at finding a new therapeutic target.

biochemistry & molecular biology
Supplementary Table S9 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic Cerna Network Related to Immune Infiltration in Sarcoma

Dongliang Leng,Ziyi Yang,Heng Sun,Chengcheng Song,Chen Huang,Ka U. Ip,Guokai Chen,Chu‐Xia Deng,Xiaohua Douglas Zhang,Qi Zhao

DOI: https://doi.org/10.1158/1078-0432.24229782.v1

2023-01-01

Abstract:Supplementary Table S9. DE miRNAs in C2 (High) compared with C1 (Low).
Abstract 7056: The role of aggressive prostate cancer risk gene ANO7 in prostate metabolism

Christoffer Löf,Nasrin Sultana,Neha Goel,Gudrun Wahlström,Johanna Schleutker

DOI: https://doi.org/10.1158/1538-7445.am2024-7056

IF: 11.2

2024-03-23

Cancer Research

Abstract:Prostate cancer (PCa), the most common male cancer worldwide, causes about 10% of cancer related deaths in Europe. It has a wide spectrum of clinical behavior that ranges from decades of indolence to rapid metastatic progression and lethality. However, the molecular mechanisms involved in aggressive PCa progression are still poorly understood. In PCa the expression of anoctamin 7 (ANO7) has been shown to diminish as the cancer progresses. We have previously linked single-nucleotide polymorphisms in the ANO7 gene to the risk of aggressive prostate cancer and shown that in homozygous carriers of rs77559646, the variant leads to a total loss of ANO7 protein. ANO7 is a prostate-specific gene and is highly expressed in the luminal cells of the human prostate. ANO7 belongs to a family of calcium-activated chloride channels and select members of the anoctamin family have phospholipid scramblase activity. To uncover the cellular functions of ANO7 has proven challenging because ANO7 is not expressed in commercially available cell lines. To study the cellular functions of ANO7, we have generated stable prostate cell lines overexpressing ANO7 using lentiviral transduction. To gain information into what pathways ANO7 is affecting, we performed RNA-sequencing and gene set enrichment analysis. Interestingly, we found enrichment and downregulation of mitochondrial genes participating in oxidative phosphorylation in ANO7 cells. We assessed the mitochondrial function by measuring the oxidative phosphorylation capability of the cells and showed that the basal and maximal respiratory capacity of ANO7 overexpressing cells is indeed reduced. We also analyzed which of the three major mitochondrial fuels (glucose, glutamine and fatty acids) are not used as efficiently for oxidative phosphorylation in ANO7 overexpressing cells. The result proves that ANO7 cells are not utilizing glucose as effectively as control cells. Furthermore, the glycolysis stress assay showed that glycolytic capacity is increased in ANO7 overexpressing cells. In addition, a targeted metabolite screening revealed that aspartate is decreased in ANO7 cells, which again points towards perturbed mitochondrial function as aspartate is produced from a tricarboxylic acid cycle intermediate. By inhibiting the uptake of extracellular aspartate, we measured slower proliferation of ANO7 expressing cells, while inhibiting aspartate had no effect on control cells. Interestingly, preliminary results also suggest ANO7's involvement in regulation of phospholipid acyl chain length and saturation, offering insights into altered signaling observed in ANO7 cells. Taken together, this study shows for the first time that ANO7 rewires prostate mitochondrial functions and thus cellular metabolism, which could explain why it is beneficial for cancer cells to lose ANO7 expression. Citation Format: Christoffer Löf, Nasrin Sultana, Neha Goel, Gudrun Wahlström, Johanna Schleutker. The role of aggressive prostate cancer risk gene ANO7 in prostate metabolism [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7056.

oncology
Supplementary Tables from MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway

Tao Yu,Yingjun Zhao,Zhixiang Hu,Jing Li,Dandan Chu,Jiwei Zhang,Zhe Li,Bing Chen,Xiao Zhang,Hongyu Pan,Shengli Li,Hechun Lin,Lei Liu,Mingxia Yan,Xianghuo He,Ming Yao

DOI: https://doi.org/10.1158/0008-5472.22418429.v1

2023-01-01

Abstract:Several tables contain the nucleotide sequences, antibodies information, LncRNA expression profiles, LncRNA screening, the correlation between MetaLnc9 and clinicopathological features, the mass spectrometric analysis results, RNA-seq analysis, KEGG and GSEA analysis.
Inhibition of Ca2+-activated Cl− Channel ANO1/TMEM16A Expression Suppresses Tumor Growth and Invasiveness in Human Prostate Carcinoma

Wen Liu,Min Lu,Baogang Liu,Yi Huang,KeWei Wang

DOI: https://doi.org/10.1016/j.canlet.2012.07.015

IF: 9.756

2012-01-01

Cancer Letters

Abstract:The etiology of prostatic adenocarcinoma remains unclear. Prostate cancer cells of varying metastatic potential and apoptotic resistance show altered expression of plasma membrane ion channels and unbalanced Ca2+ homeostasis. Ca2+-activated Cl- channels (CaCCs) are robustly expressed in epithelial cells and function to regulate epithelial secretion and cell volume for maintenance of ion and tissue homeostasis in proliferation, differentiation and apoptosis. ANO1/TMEM16A was recently identified as a CaCC, and it is of interest to determine whether ANO1 plays a role in development and metastasis of prostate carcinoma. Here we show that ANO1 mRNA and protein are highly expressed in human metastatic prostate cancer LNCaP and PC-3 cells by quantitative analysis of real-time PCR and Western blot. These findings were confirmed by whole-cell patch clamp recording of LNCaP and PC-3 cells with increased current density of ANO1 channels. Immunohistochemistry staining further revealed overexpression of ANO1 in human prostate cancer tissues, which correlated with the clinical TNM stage and Gleason score. Experiments with small hairpin RNAs (shRNAs) targeting human ANO1 resulted in a significant reduction of proliferation, metastasis and invasion of PC-3 cells using WST-8, colony formation, wound-healing and transwell assays. Moreover, intratumoral injection of ANO1 shRNA completely inhibited established tumor growth and survival in orthotopic nude mice implanted with PC-3 cells. Our findings provide compelling evidence that upregulation of CaCC ANO1 is involved in the proliferation, progression and pathogenesis of metastatic prostate cancer. Membrane ANO1 protein may therefore serve as a biomarker, and inhibition of overexpressed ANO1 has potential for use in prostate cancer therapy. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
Supplementary Table S16 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic Cerna Network Related to Immune Infiltration in Sarcoma

Dongliang Leng,Ziyi Yang,Heng Sun,Chengcheng Song,Chen Huang,Ka U. Ip,Guokai Chen,Chu-Xia Deng,Xiaohua Douglas Zhang,Qi Zhao

DOI: https://doi.org/10.1158/1078-0432.24229812.v1

2023-01-01

Abstract:Supplementary Table S16. Cell types determination based on different annotation references.
Supplementary Table 1 from NCOA1 Directly Targets M-CSF1 Expression to Promote Breast Cancer Metastasis

Li Qin,Ye-Lin Wu,Michael J. Toneff,Dabing Li,Lan Liao,Xiuhua Gao,Fiona T. Bane,Jean C.-Y. Tien,Yixiang Xu,Zhen Feng,Zhihui Yang,Yan Xu,Sarah M. Theissen,Yi Li,Leonie Young,Jianming Xu

DOI: https://doi.org/10.1158/0008-5472.22399154

2023-01-01

Abstract:PDF file - 93KB, PCR Primers and TaqMan qPCR Probes.

Supplementary Table 7 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis

Supplementary Table 6 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis

Supplementary Table 5 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis

ANO1 reprograms cholesterol metabolism and the tumor microenvironment to promote cancer metastasis

High ANO1 expression is a prognostic factor and correlated with an immunosuppressive tumor microenvironment in pancreatic cancer

Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Identification And Characterization Of Ano9 In Stage Ii And Iii Colorectal Carcinoma

Table S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

ANO1‐Mediated Inhibition of Cancer Ferroptosis Confers Immunotherapeutic Resistance through Recruiting Cancer‐Associated Fibroblasts

Role of ANO1 in Tumors and Tumor Immunity

Supplementary Table 1 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER<sup>+</sup> Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Figure S6 from Consistent and Differential Genetic Aberrations between Esophageal Dysplasia and Squamous Cell Carcinoma Detected By Array Comparative Genomic Hybridization

High level of ANO1 promotes pancreatic cancer growth in concert with oncogenic KRAS

Supplementary Table S9 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic Cerna Network Related to Immune Infiltration in Sarcoma

Abstract 7056: The role of aggressive prostate cancer risk gene ANO7 in prostate metabolism

Supplementary Tables from MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway

Inhibition of Ca2+-activated Cl− Channel ANO1/TMEM16A Expression Suppresses Tumor Growth and Invasiveness in Human Prostate Carcinoma

Supplementary Table S16 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic Cerna Network Related to Immune Infiltration in Sarcoma

Supplementary Table 1 from NCOA1 Directly Targets <i>M-CSF1</i> Expression to Promote Breast Cancer Metastasis

Supplementary Table 7 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis

Supplementary Table 6 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis

Supplementary Table 5 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis

ANO1 reprograms cholesterol metabolism and the tumor microenvironment to promote cancer metastasis

High ANO1 expression is a prognostic factor and correlated with an immunosuppressive tumor microenvironment in pancreatic cancer

Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Identification And Characterization Of Ano9 In Stage Ii And Iii Colorectal Carcinoma

Table S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

ANO1‐Mediated Inhibition of Cancer Ferroptosis Confers Immunotherapeutic Resistance through Recruiting Cancer‐Associated Fibroblasts

Role of ANO1 in Tumors and Tumor Immunity

Supplementary Table 1 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER&lt;sup&gt;+&lt;/sup&gt; Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Figure S6 from Consistent and Differential Genetic Aberrations between Esophageal Dysplasia and Squamous Cell Carcinoma Detected By Array Comparative Genomic Hybridization

High level of ANO1 promotes pancreatic cancer growth in concert with oncogenic KRAS

Supplementary Table S9 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic Cerna Network Related to Immune Infiltration in Sarcoma

Abstract 7056: The role of aggressive prostate cancer risk gene ANO7 in prostate metabolism

Supplementary Tables from MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway

Inhibition of Ca2+-activated Cl− Channel ANO1/TMEM16A Expression Suppresses Tumor Growth and Invasiveness in Human Prostate Carcinoma

Supplementary Table S16 from Comprehensive Analysis of Tumor Microenvironment Reveals Prognostic Cerna Network Related to Immune Infiltration in Sarcoma

Supplementary Table 1 from NCOA1 Directly Targets &lt;i&gt;M-CSF1&lt;/i&gt; Expression to Promote Breast Cancer Metastasis

Supplementary Table 1 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER<sup>+</sup> Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplementary Table 1 from NCOA1 Directly Targets <i>M-CSF1</i> Expression to Promote Breast Cancer Metastasis